Aceclofenac – the use in relieving chronic pain in patients with osteoarthritis, ankylosing spondylitis and rheumatoid arthritis Case series report
Main Article Content
Abstract
Aceclofenac is nonsteroidal anti-inflammatory drug, selective COX-2 inhibitor with strong analgesic and anti-inflammatory effect. According to characteristics of the medical product and it’s unique chondroprotective properties it is recommended in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
Article Details
How to Cite
Kucia, H., & Sękowska , A. (2013). Aceclofenac – the use in relieving chronic pain in patients with osteoarthritis, ankylosing spondylitis and rheumatoid arthritis. Medycyna Faktow (J EBM), 6(3(20), 16-22. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2402
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Dooley M., Spencer C.M., Dunn C.J.: Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs 2001; 61: 1351-1378.
2. Hinz B., Brune K.: Pain and osteoarthritis: new drugs and mechanisms. Curr. Opin. Rheum. 2004; 16(5): 628-633.
3. Dingle J.T., Parker M.: NSAID stimulation of human cartilage matrix synthesis – a study of the mechanism of action of aceclofenac. Clin. Drug. Invest. 1997; 14: 353-362.
4. Blot L., Marcelis A., Devogelaer J.P., Manicourt D.H.: Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br. J. Pharmacol. 2000; 131: 1413-1421.
5. Legrand E.: Aceclofenac in the management of inflammatory pain. Expert Opin. Pharmacother. 2004; 5(6): 1347-1357.
6. Pareek A.,Chandurkar N.: Comparison of gastrointestinal safety and tolerability of aceclofenac with diclofenac: a multicenter, randomized, double- blind study in patients with knee osteoarthritis. Gastroenterology 2013; 29(7): 849-859.
7. Hinz B., Rau T., Auge D. et al.: Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin. Pharmacol. Ther. 2003; 74: 222-235.
8. Kompendium leczenia bólu. Malec-Milewska M., Woroń J. (red.). Medical Education Sp. z o.o., Warszawa 2012.
9. Rupiński R.: Aceklofenak – działanie chondroprotekcyjne w chorobie zwyrodnieniowej stawów. Medycyna Faktów 2013; 6(18).
10. Maneiro E., López-Armada M.J., Fernández-Sueiro J.L. et al.: Aceclofenac increases the synthesis of interleukin 1 receptor antagonist and decreases the production of nitric oxide in human articular chondrocytes. J. Rheumatol. 2001; 28(12): 2692-2699.
11. Henrotin Y., de Leval X., Mathy-Hartet M. et al.: In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators. Inflamm. Res. 2001; 50: 391-399.
12. Choroby wewnętrzne 2013. Gajewski P. (red.). Medycyna Praktyczna 2013.
13. Rupiński R.: Wpływ aceklofenaku na chrząstkę stawową na tle wpływu innych niesteroidowych leków przeciwzapalnych. Medycyna Faktów 2013; 6(18).
2. Hinz B., Brune K.: Pain and osteoarthritis: new drugs and mechanisms. Curr. Opin. Rheum. 2004; 16(5): 628-633.
3. Dingle J.T., Parker M.: NSAID stimulation of human cartilage matrix synthesis – a study of the mechanism of action of aceclofenac. Clin. Drug. Invest. 1997; 14: 353-362.
4. Blot L., Marcelis A., Devogelaer J.P., Manicourt D.H.: Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br. J. Pharmacol. 2000; 131: 1413-1421.
5. Legrand E.: Aceclofenac in the management of inflammatory pain. Expert Opin. Pharmacother. 2004; 5(6): 1347-1357.
6. Pareek A.,Chandurkar N.: Comparison of gastrointestinal safety and tolerability of aceclofenac with diclofenac: a multicenter, randomized, double- blind study in patients with knee osteoarthritis. Gastroenterology 2013; 29(7): 849-859.
7. Hinz B., Rau T., Auge D. et al.: Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin. Pharmacol. Ther. 2003; 74: 222-235.
8. Kompendium leczenia bólu. Malec-Milewska M., Woroń J. (red.). Medical Education Sp. z o.o., Warszawa 2012.
9. Rupiński R.: Aceklofenak – działanie chondroprotekcyjne w chorobie zwyrodnieniowej stawów. Medycyna Faktów 2013; 6(18).
10. Maneiro E., López-Armada M.J., Fernández-Sueiro J.L. et al.: Aceclofenac increases the synthesis of interleukin 1 receptor antagonist and decreases the production of nitric oxide in human articular chondrocytes. J. Rheumatol. 2001; 28(12): 2692-2699.
11. Henrotin Y., de Leval X., Mathy-Hartet M. et al.: In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators. Inflamm. Res. 2001; 50: 391-399.
12. Choroby wewnętrzne 2013. Gajewski P. (red.). Medycyna Praktyczna 2013.
13. Rupiński R.: Wpływ aceklofenaku na chrząstkę stawową na tle wpływu innych niesteroidowych leków przeciwzapalnych. Medycyna Faktów 2013; 6(18).